[Preliminary application of carbohydrate antigen CA-50 radioimmunoinhibition test in diagnosing and monitoring cancers].
Serum CA-50 antigen in the normal individuals and cancer patients was assayed by radioimmunoassay. CA-50, one type of carbohydrate antigens, consisting mainly of sialylated glycolipid (a ganglioside) and sialylated glycoprotein, can be isolated from the primary or metastatic tumors. Using the latest CA-50 antigen radioimmunoinhibition test kits prepared by Steana Diagnostics AB Company, Sweden, the serum CA-50 content was measured in 62 normal individuals, 9 primary hepatocellular carcinomas, 9 liver benign tumors, 23 ovarian or uterine carcinomas, 22 other malignancies and 21 benign tumors. The normal value was 6.05 +/- 4.93 U/ml. The test values in cancer patients were significantly higher than those in normals or benign tumor patients. Taking the normal mean value plus two times of standard deviation as positive, the positive rate was 77.7% for liver cancer, 65.2% for ovary and uterus carcinomas, 50% for the other cancers. There was only one positive in 62 normals with a false positive rate of 1.6%. Furthermore, 19 patients, being in the remission period or cured by effective treatment, gave normal CA-50 value. It is shown that this method can be used in cancer diagnosis, differential diagnosis and the monitor, prediction of prognosis.